296 related articles for article (PubMed ID: 9263143)
21. Interleukin 2 and interleukin 2 inhibitors in human serum and synovial fluid. II. Mitogenic stimulation, interleukin 2 production and interleukin 2 receptor expression in rheumatoid arthritis, psoriatic arthritis and Reiter's syndrome.
Smith MD; Roberts-Thomson PJ
J Rheumatol; 1989 Jul; 16(7):897-903. PubMed ID: 2788742
[TBL] [Abstract][Full Text] [Related]
22. Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture.
Matsumiya T; Imaizumi T; Fujimoto K; Cui X; Shibata T; Tamo W; Kumagai M; Tanji K; Yoshida H; Kimura H; Satoh K
Exp Cell Res; 2001 Sep; 269(1):35-41. PubMed ID: 11525637
[TBL] [Abstract][Full Text] [Related]
23. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
Wierzbowska A; Urbańska-Ryś H; Robak T
Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
[TBL] [Abstract][Full Text] [Related]
24. Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes.
Gabay C; Silacci P; Genin B; Mentha G; Le Coultre C; Guerne PA
Eur J Immunol; 1995 Aug; 25(8):2378-83. PubMed ID: 7545121
[TBL] [Abstract][Full Text] [Related]
25. Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment.
Jablonska E
Cytokine; 1998 Jul; 10(7):540-3. PubMed ID: 9702418
[TBL] [Abstract][Full Text] [Related]
26. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
[TBL] [Abstract][Full Text] [Related]
27. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition.
Symons JA; Wood NC; Di Giovine FS; Duff GW
J Immunol; 1988 Oct; 141(8):2612-8. PubMed ID: 3262665
[TBL] [Abstract][Full Text] [Related]
28. Synovial fluid induced nuclear factor-kappaB DNA binding in a monocytic cell line.
Lehmann T; Nguyen LQ; Handel ML
J Rheumatol; 2000 Dec; 27(12):2769-76. PubMed ID: 11128662
[TBL] [Abstract][Full Text] [Related]
29. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
[TBL] [Abstract][Full Text] [Related]
30. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
Mathsson L; Lampa J; Mullazehi M; Rönnelid J
Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
[TBL] [Abstract][Full Text] [Related]
31. Interleukin 1 in rheumatoid arthritis: potentiation of immune responses within the joint.
Symons JA; McDowell TL; di Giovine FS; Wood NC; Capper SJ; Duff GW
Lymphokine Res; 1989; 8(3):365-72. PubMed ID: 2789325
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
[TBL] [Abstract][Full Text] [Related]
33. Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis.
Saxena N; Aggarwal A; Misra R
J Rheumatol; 2005 Jul; 32(7):1349-53. PubMed ID: 15996076
[TBL] [Abstract][Full Text] [Related]
34. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
[TBL] [Abstract][Full Text] [Related]
35. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine.
Ikeuchi H; Kuroiwa T; Hiramatsu N; Kaneko Y; Hiromura K; Ueki K; Nojima Y
Arthritis Rheum; 2005 Apr; 52(4):1037-46. PubMed ID: 15818686
[TBL] [Abstract][Full Text] [Related]
36. Soluble interleukin-6 receptor in plasma and in lymphocyte culture supernatants of healthy individuals and patients with systemic lupus erythematosus and rheumatoid arthritis.
Polgár A; Brózik M; Tóth S; Holub M; Hegyi K; Kádár A; Hodinka L; Falus A
Med Sci Monit; 2000; 6(1):13-8. PubMed ID: 11208277
[TBL] [Abstract][Full Text] [Related]
37. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal.
Suzuki H; Yasukawa K; Saito T; Narazaki M; Hasegawa A; Taga T; Kishimoto T
Eur J Immunol; 1993 May; 23(5):1078-82. PubMed ID: 8477802
[TBL] [Abstract][Full Text] [Related]
38. Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis.
Yamamura M; Kawashima M; Taniai M; Yamauchi H; Tanimoto T; Kurimoto M; Morita Y; Ohmoto Y; Makino H
Arthritis Rheum; 2001 Feb; 44(2):275-85. PubMed ID: 11229457
[TBL] [Abstract][Full Text] [Related]
39. Role of interleukin-15 and interleukin-18 in the secretion of sIL-6R and sgp130 by human neutrophils.
Jablonska E; Marcinczyk M
Mediators Inflamm; 2003 Jun; 12(3):179-83. PubMed ID: 12857602
[TBL] [Abstract][Full Text] [Related]
40. Interleukin 16 expression in relation to disease activity in rheumatoid arthritis.
Blaschke S; Schulz H; Schwarz G; Blaschke V; Müller GA; Reuss-Borst M
J Rheumatol; 2001 Jan; 28(1):12-21. PubMed ID: 11196512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
